Limoneira Company (LMNR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Limoneira Company on October 26, 2021. The filing addresses corporate governance updates, specifically the expansion of the Board of Directors and amendments to the Company's Bylaws.
Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Board Expansion: The Board of Directors expanded its size from ten to eleven directors, creating a vacancy filled by the appointment of Elizabeth Mora as a Class III director, effective November 1, 2021.
- Bylaw Amendments: The Board adopted Amended and Restated Bylaws effective October 26, 2021. Key changes include:
- Flexibility to schedule the annual meeting at any date, time, and place determined by the Board, removing the previous requirement to hold it on the fourth Tuesday of March.
- Authority for the Board to set the number of directors between a range of six and twelve, replacing the fixed size of ten.
- Authorization for any two authorized officers to sign stock certificates, broadening the previous restriction to specific executive titles.
Outlook, Risks, and Management Commentary
Management highlighted that Ms. Mora brings extensive executive experience in finance and administration from her previous roles at The Charles Stark Draper Laboratory and Harvard University. The Board stated these changes reflect current legal requirements and corporate governance best practices. No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the effective date of Elizabeth Mora's directorship (November 1, 2021) and her term expiration (2023 Annual Meeting).
- Review the full text of the Amended and Restated Bylaws (Exhibit 3.1) for non-substantive technical revisions not detailed in the summary.
- Confirm that Ms. Mora's compensation aligns with the standard non-management director fees disclosed in the February 12, 2021, Schedule 14A proxy statement.
- Note that this filing contains no financial results; investors should refer to the most recent 10-Q or 10-K for financial metrics.